Contacts
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela (XINT) is a publicly-traded clinical-stage biopharma company, that develops cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela’s proprietary technology uses the stem cell marker integrin α10β1 to select and quality-assure the stem cell product XSTEM®, which has shown safety and positive efficacy results in clinical study on knee osteoarthritis and has now completed clinical study on difficult-to-heal leg ulcers. Xintela’s in-house GMP-facility manufactures XSTEM and generates revenues by providing process development and manufacturing of other cell therapies. Xintela’s wholly owned subsidiary Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult to treat cancers including triple-negative breast cancer and brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm. Xintela’s Certified Adviser is Tapper Partners AB.
